相似文献
1
Coordinate hyperproduction of SmeZ and SmeJK efflux pumps extends drug resistance in Stenotrophomonas maltophilia.
Antimicrob Agents Chemother. 2013 Jan;57(1):655-7. doi: 10.1128/AAC.01020-12. Epub 2012 Nov 12.
2
Levofloxacin Efflux and smeD in Clinical Isolates of Stenotrophomonas maltophilia.
Microb Drug Resist. 2017 Mar;23(2):163-168. doi: 10.1089/mdr.2015.0228. Epub 2016 Jun 13.
3
Resistance of Stenotrophomonas maltophilia to Fluoroquinolones: Prevalence in a University Hospital and Possible Mechanisms.
Int J Environ Res Public Health. 2015 May 13;12(5):5177-95. doi: 10.3390/ijerph120505177.
4
Overexpression of SmeGH contributes to the acquired MDR of Stenotrophomonas maltophilia.
J Antimicrob Chemother. 2019 Aug 1;74(8):2225-2229. doi: 10.1093/jac/dkz200.
5
Overexpression of SmeDEF Efflux Pump Decreases Aminoglycoside Resistance in Stenotrophomonas maltophilia.
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02685-16. Print 2017 May.
6
Multidrug-resistant Stenotrophomonas maltophilia: Description of new MLST profiles and resistance and virulence genes using whole-genome sequencing.
J Glob Antimicrob Resist. 2018 Dec;15:212-214. doi: 10.1016/j.jgar.2018.07.009. Epub 2018 Jul 20.
7
Overexpression of Stenotrophomonas maltophilia major facilitator superfamily protein MfsA increases resistance to fluoroquinolone antibiotics.
J Antimicrob Chemother. 2018 May 1;73(5):1263-1266. doi: 10.1093/jac/dky024.
8
Expression of Sme efflux pumps and multilocus sequence typing in clinical isolates of Stenotrophomonas maltophilia.
Ann Lab Med. 2012 Jan;32(1):38-43. doi: 10.3343/alm.2012.32.1.38. Epub 2011 Dec 20.
9
Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland.
Br J Biomed Sci. 2005;62(1):30-2. doi: 10.1080/09674845.2005.11978067.
10
Contribution of integrons, and SmeABC and SmeDEF efflux pumps to multidrug resistance in clinical isolates of Stenotrophomonas maltophilia.
J Antimicrob Chemother. 2004 Mar;53(3):518-21. doi: 10.1093/jac/dkh094. Epub 2004 Jan 28.
引用本文的文献
1
RND/HAE-1 members in the Pseudomonadota phylum: exploring multidrug resistance.
Biophys Rev. 2025 Mar 7;17(2):687-699. doi: 10.1007/s12551-025-01297-8. eCollection 2025 Apr.
2
Clinical presentation and outcomes of bloodstream infection with intrinsically carbapenem-resistant non-fermenting gram-negative organisms: Stenotrophomonas maltophilia, Elizabethkingia spp. and Chryseobacterium spp. in Singapore, from 2012 to 2024.
BMC Infect Dis. 2025 Feb 25;25(1):273. doi: 10.1186/s12879-025-10636-9.
3
Multidrug-resistant Stenotrophomonas maltophilia in residential aged care facilities: An emerging threat.
Microbiologyopen. 2024 Jun;13(3):e1409. doi: 10.1002/mbo3.1409.
4
Efflux pumps as potential targets for biofilm inhibition.
Front Microbiol. 2024 Feb 23;15:1315238. doi: 10.3389/fmicb.2024.1315238. eCollection 2024.
5
A guide to virulence capabilities, as we currently understand them.
Front Cell Infect Microbiol. 2024 Jan 11;13:1322853. doi: 10.3389/fcimb.2023.1322853. eCollection 2023.
6
Antimicrobial Resistance: Two-Component Regulatory Systems and Multidrug Efflux Pumps.
Antibiotics (Basel). 2023 May 26;12(6):965. doi: 10.3390/antibiotics12060965.
7
Versatility of : Ecological roles of RND efflux pumps.
Heliyon. 2023 Mar 28;9(4):e14639. doi: 10.1016/j.heliyon.2023.e14639. eCollection 2023 Apr.
8
Plant Secondary Metabolites on Efflux-Mediated Antibiotic Resistant : Potential of Herbal-Derived Efflux Pump Inhibitors.
Antibiotics (Basel). 2023 Feb 20;12(2):421. doi: 10.3390/antibiotics12020421.
9
The Contribution of Efflux Systems to Levofloxacin Resistance in Clinical Strains Isolated in Warsaw, Poland.
Biology (Basel). 2022 Jul 12;11(7):1044. doi: 10.3390/biology11071044.
10
Does Chlorination Promote Antimicrobial Resistance in Waterborne Pathogens? Mechanistic Insight into Co-Resistance and Its Implication for Public Health.
Antibiotics (Basel). 2022 Apr 22;11(5):564. doi: 10.3390/antibiotics11050564.
本文引用的文献
1
Antibiotic treatment of CF lung disease: from bench to bedside.
J Cyst Fibros. 2011 Jun;10 Suppl 2:S146-51. doi: 10.1016/S1569-1993(11)60019-2.
2
Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections.
Antimicrob Agents Chemother. 2010 Jun;54(6):2735-7. doi: 10.1128/AAC.01774-09. Epub 2010 Apr 5.
3
Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005.
J Cyst Fibros. 2009 Dec;8(6):386-91. doi: 10.1016/j.jcf.2009.08.003. Epub 2009 Sep 8.
4
The versatility and adaptation of bacteria from the genus Stenotrophomonas.
Nat Rev Microbiol. 2009 Jul;7(7):514-25. doi: 10.1038/nrmicro2163.
5
Stenotrophomonas maltophilia: an emerging opportunist human pathogen.
Lancet Infect Dis. 2009 May;9(5):312-23. doi: 10.1016/S1473-3099(09)70083-0.
6
The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants.
Genome Biol. 2008 Apr 17;9(4):R74. doi: 10.1186/gb-2008-9-4-r74.
7
Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator.
Antimicrob Agents Chemother. 2008 Apr;52(4):1525-8. doi: 10.1128/AAC.01485-07. Epub 2008 Jan 22.
8
Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes.
Emerg Infect Dis. 2007 Apr;13(4):559-65. doi: 10.3201/eid1304.061378.
9
Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
Antimicrob Agents Chemother. 2007 Jan;51(1):359-60. doi: 10.1128/AAC.00795-06. Epub 2006 Nov 6.
10
SmeDEF-mediated antimicrobial drug resistance in Stenotrophomonas maltophilia clinical isolates having defined phylogenetic relationships.
J Antimicrob Chemother. 2006 Jun;57(6):1070-6. doi: 10.1093/jac/dkl106. Epub 2006 Apr 5.
Zotero 插件